Denali Therapeutics Inc.(DNLI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DNLI Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Denali Therapeutics Inc. (DNLI), a Healthcare sector company. DNLI is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Denali Therapeutics Inc. reports quarterly revenue of $3.6M, net income of $-127.6M, free cash flow of $-97.8M. Top institutional holders of DNLI by reported 13-F value include T. Rowe Price Investment Management, BlackRock, BAILLIE GIFFORD, based on the most recent SEC filings. DNLI trades on the Nasdaq exchange and files with the SEC under CIK 1714899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNLI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Denali Therapeutics Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$3.6M
Net Income
Q2 2026
$-127.6M
Free Cash Flow
Q2 2026
$-97.8M
ROIC
Q2 2026
-62.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-21.2% YoYOperating Income
-14.0% YoYEPS (Diluted)
-15.6% YoYTotal Assets
-16.7% YoYOp. Cash Flow
-18.7% YoYFree Cash Flow
-16.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 -100.0% | $330.5M +204.7% | $108.5M +122.9% | $48.7M -85.5% | $335.7M |
| Net Income | $-512.5M -21.2% | $-422.8M -191.1% | $-145.2M +55.5% | $-326.0M -12.2% | $-290.6M -508.5% | $71.1M |
| Operating Income | $-555.3M -14.0% | $-487.3M -147.8% | $-196.7M +42.3% | $-340.7M -15.2% | $-295.8M -571.6% | $62.7M |
| EPS (Diluted) | $-2.97 -15.6% | $-2.57 -142.5% | $-1.06 +59.2% | $-2.60 -8.8% | $-2.39 -479.4% | $0.63 |
| Total Assets | $1.14B -16.7% | $1.37B +19.1% | $1.15B -21.0% | $1.46B +4.0% | $1.40B -12.5% | $1.60B |
| Operating Cash Flow | $-412.6M -18.7% | $-347.7M +2.9% | $-358.0M -46.3% | $-244.7M -15.8% | $-211.4M -150.8% | $416.2M |
| Free Cash Flow | $-422.1M -16.1% | $-363.6M +2.0% | $-370.9M -41.3% | $-262.5M -19.4% | $-219.9M -153.2% | $413.1M |
Get alerted when DNLI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Denali Therapeutics Inc. including:
Top Institutional Holders of DNLI
T. Rowe Price Investment Management, Inc.
$416.1M16,178,963 shBlackRock, Inc.
$360.8M14,026,413 shBAILLIE GIFFORD & CO
$307.6M11,960,230 shSTATE STREET CORP
$181.3M7,049,304 shTemasek Holdings (Private) Ltd
$180.4M7,012,974 shVANGUARD PORTFOLIO MANAGEMENT LLC
$166.6M6,477,057 shVANGUARD CAPITAL MANAGEMENT LLC
$161.4M6,275,729 shFMR LLC
$116.7M4,535,836 shGOLDMAN SACHS GROUP INC
$106.9M4,155,895 shGEODE CAPITAL MANAGEMENT, LLC
$102.2M3,973,342 sh
| Fund | Value | Shares |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | $416.1M | 16,178,963 |
| BlackRock, Inc. | $360.8M | 14,026,413 |
| BAILLIE GIFFORD & CO | $307.6M | 11,960,230 |
| STATE STREET CORP | $181.3M | 7,049,304 |
| Temasek Holdings (Private) Ltd | $180.4M | 7,012,974 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $166.6M | 6,477,057 |
| VANGUARD CAPITAL MANAGEMENT LLC | $161.4M | 6,275,729 |
| FMR LLC | $116.7M | 4,535,836 |
| GOLDMAN SACHS GROUP INC | $106.9M | 4,155,895 |
| GEODE CAPITAL MANAGEMENT, LLC | $102.2M | 3,973,342 |
More Healthcare Companies
View all Healthcare →Put DNLI on your watchlist
Track score changes the day Denali Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DNLI a good stock to buy?
13F Pro's AI-powered analysis of Denali Therapeutics Inc. (DNLI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNLI are available on the DNLI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DNLI is classified as a mid company.
Which hedge funds own DNLI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNLI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Denali Therapeutics Inc.'s investment landscape.